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Urinary metabolomic changes as a predictive
biomarker of asthma exacerbation
To the Editor:
Exacerbations requiring hospitalization represent a high risk
in patients with severe asthma. Predictive biomarkers ofFIG 1. PCAapplied toGC3GCpeak areas of aliphatic ald
in the stable state and under exacerbation conditions. A
sponds to the control condition (open symbols) and e
numbers included close to the symbols correspond to th
aration observed in the score map (positive loadings 5exacerbations are needed but are not available. Oxidative stress
resulting from pulmonary reactive oxygen species formation is
involved in asthma, leading to physiologic damage.1 Asthma
exacerbation is associated with increased oxidative stress,2 with
increased levels of carbon monoxide, nitric oxide, nitrotyrosine,
and H2O2 found in breath condensate. Aldehydes and alkanes,
the end products of lipid peroxidation, are also known to be
involved in asthma-related oxidative stress.3
Urine is a stable, noninvasively collectable body fluid with a
complexmetabolic composition, the profiling of whichmight have
a role in asthmadiagnosis andmonitoring.The 2 techniques used in
this study, comprehensive bidimensional gas chromatography
coupled to mass spectrometry (GC 3 GC-ToFMS) and proton
nuclear magnetic resonance (1H-NMR) spectroscopy, allow the
analysis of volatile and nonvolatile compounds, thus providing
complementary information on the urinary metabolome.
The aim of this pilot study was to assess the urinary metabolic
changes linked to asthma exacerbation. Aldehydes and alkanes
were studied by using GC3 GC-ToFMS analysis, and NMR was
used to provide an overview of changes in major metabolites
involved in central metabolic pathways.ehydes andalkanes detected in the urine of subjects
, PC1 versus PC2 score scatter plot in which c corre-
corresponds to exacerbation (solid symbols). The
e sample ID.B, PC1 loadings plot explaining the sep-
compounds increased in exacerbated condition).
AB
FIG 2. PCA applied to 1H-NMR urine spectra of subjects in the stable state and under exacerbation condi-
tions. A, PC1 versus PC2 score scatter plot. Arrows highlight the direction of change from stable (open sym-
bols) to exacerbation (solid symbols) conditions for each subject. The numbers included close to the
symbols correspond to the sample ID. B, PC1 loadings plot explaining the separation observed in the score
map (positive loadings 5 compounds increased in stable conditions; negative loadings - compounds
increased in exacerbated conditions).
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Written informed consent was provided, as was approval from the
ethics board of the Hospitais da Universidade de Coimbra. All of
the patients had a definite diagnosis of asthma (see the Methods
section in this article’s Online Repository at www.jacionline.
org). All patients were studied at 2 different stages: during exac-
erbation (see the Methods section in this article’s Online Repos-
itory at www.jacionline.org) and during a control state, as
defined by results of the Asthma Control Test.
Urine was collected during exacerbation and in the stable state
(see the Methods section in this article’s Online Repository). All
samples were analyzed by using solid-phase microextraction
(SPME)/GC 3 GC-ToFMS,4 and samples from 5 of 10 subjects
were also analyzed by using 1H-NMR spectroscopy (see the
Methods section in this article’s Online Repository).5
Exploratory principal component analysis (PCA) was applied
to GC3GC peak areas, as well as to 1H-NMR spectra, to extract
the metabolic features of the exacerbation (see the Methods
section in this article’s Online Repository).
All patients (5 male and 5 female patients; mean age, 506 18.8
years) were treated before exacerbation with inhaled corticoste-
roids and long-acting b-agonists. Seven patients had an allergicphenotype (see Table E1 in this article’s Online Repository at
www.jacionline.org).
PCA was applied to data matrices comprising aliphatic
aldehydes and alkanes (Fig 1; and see Table E2 in this article’s
Online Repository at www.jacionline.org). The score scatter
plot of the first and second principal components (PC1 and
PC2; Fig 1, A), explaining 40% of the total variability, show the
separation of exacerbation-related samples from control samples
along PC1. The corresponding PC1 loadings (Fig 1, B) show that
subjects under the exacerbated conditions were characterized by
higher levels of alkanes and aldehydes. For 9 of the subjects, the
aldehyde and alkane content consistently increased in the exacer-
bation state compared with the stable condition (see Fig E1 in this
article’s Online Repository at www.jacionline.org).
The 1H-NMR spectrum shows signals from several amino acids
and derivatives, organic acids, amines, and other metabolites,
such as glucose and creatinine (see Fig E2 in this article’s Online
Repository at www.jacionline.org). The score scatter plot of the 2
main PCs (explaining almost 50% of the total variability) shows,
for each subject, a clear trend for sample scores to shift from the
positive to the negative PC1 axis between stable and exacerbated
conditions (Fig 2, A). The PC1 loadings plot unveiled the signals
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lactate), alanine, carnitine, acetylcarnitine, and trimethylamine-
N-oxide were suggested to be increased in the exacerbated
condition, whereas levels of acetate, citrate, malonate, hippurate,
dimethylglycine, and phenylacetylglutamine seemed to be
decreased compared with the stable condition (Fig 2, B).
During exacerbations, urine revealed increased levels of
aldehydes and alkanes, as well as alterations in a number of
nonvolatile metabolites.
As for limitations and strengths of this study, diet and current
treatment might interfere with the urine metabolomic profile. No
food restriction was made. Despite all patients having a similar
initial dose of methylprednisolone (approximately 80 mg/d), this
remains a confounding factor. Further studies with a larger
population are necessary to confirm these findings.
The use of 2 high-throughput techniques used in this study
provides complementary information, enhancing the current
understanding of themetabolic pathways affected (see the Results
and discussion, Limitations and strengths section, in this article’s
Online Repository at www.jacionline.org).
Alkanes and aldehydes, end products of the peroxidation of
unsaturated fats, can be formed during inflammation. Their levels
were found to be increased during exacerbation, suggesting a high
level of oxidative stress compared with the stable state (see the
Results and discussion, Data interpretation section, in this
article’s Online Repository at www.jacionline.org).
Carnitine and acetylcarnitine can be linked to increased
oxidative burden because they play an essential role in the
transport of fatty acids into mitochondria for oxidation. These
metabolites are critically altered in asthmatic patients.2 More-
over, changes in metabolites, such as citrate and alanine, suggest
a disturbance of the tricarboxylic acid cycle, whereas altered
levels of trimethylamine-N-oxide, hippurate, and phenylacetyl-
glutamine might be related to diet.
Urine is an easily accessible and information-rich biofluid. Our
preliminary data show that urine metabolomics might provide
important information on the patients’ oxidative stress status.
They also show promise in asthma management. This would
suggest that research on metabolomic signatures in a broader
group of asthmatic patients, including different phenotypes and
disease presentation, might be valuable.
In conclusion, urinarymetabolic compositionwas highly altered
during exacerbation comparedwith that seen in the stable state. GC
3 GC-TOFMS– and 1H-NMR–based methodologies allowed
complementary information to be retrieved. In spite of the limited
number of cases considered, the present results suggest that oxida-
tive stress is a fundamental factor in asthma exacerbation.
We thank the Portuguese National NMR Network (RNRMN), which is
supported with FCT funds, and Sigma-Aldrich for the provision of GC
columns and standards.
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Unsuspected mild emphysema in nonsmoking
patients with chronic asthma with persistent
airway obstruction
To the Editor:
We have previously demonstrated that reversible loss of lung
elastic recoil is a significant contributing factor in limitingmaximal
expiratory airflow in acute asthma.1We2 and others3-7 have also re-
ported chronic loss of lung elastic recoil in clinically stable,
nonsmoking, adult patients with moderate-to-severe asthma with
persistent expiratory airflow limitation thatmay be partially revers-
ible with treatment. The mechanism(s) responsible for the loss of
lung elastic recoil in acute1 and chronic asthma2-7 remains un-
known, especially with normal diffusing capacity and normal or
only mild parenchymal attenuation of lung density on high-
resolution thin-section lung computed tomography (CT) at full
inspiration.2Here, in a prospective study,we investigated the poten-
tial pathophysiologic mechanism(s) limiting maximal expiratory
airflow (VmaxE) after optimal clinical improvement. Our hypothe-
sis is that undiagnosed diffuse breakdown of lung tissue leading to
mild, diffuse emphysema may be responsible for both the loss of
lung elastic recoil and persistent expiratory airflow limitation.
METHODS
Patients’ characteristics
Adults with asthma were recruited from the emergency department of
Hospitais da Universidade de Coimbra, where they were treated for an asthma
attack. All had a clinical asthma diagnosis based on relevant respiratory
symptoms plus airway reversibility to salbutamol according to Global
Initiative for Asthma guidelines, a provocative dose of methacholine resulting
in a 20% reduction in FEV1 of less than 8 mmol, or both. None of them had
signs of bacterial respiratory tract infection.
Exacerbation was defined on the basis of increasing asthma symptoms or
insufficient symptomatic response to inhaled bronchodilator therapy and the
need for systemic corticosteroids. At discharge, they all had a similar systemic
oral corticosteroid regression scheme. Each asthmatic patientwas referred to an
asthma specialist clinician, and the stable periodwas defined in a clinical setting
havingmet clinical criteria and an appropriate score on theAsthmaControl Test
(>_20). None of them were receiving systemic corticosteroids at the time.
Patientswith skin prick test responses or specific IgE levels positive for at least 1
commonaeroallergenwere considered allergic byusing theGA2LENbattery.E1
Urine sample collection
Two urine samples were collected from each asthmatic patient: one sample
during the exacerbation period (in the first 4 hours after emergency department
presentation or systemic corticosteroid administration) and the other during
the stable period (6-8 weeks after). Urine samples were collected in sterile
cups, stored at 2208C for 2 hours, and then transferred to a 2808C freezer,
where they were stored for up to 3 months before analysis. The time of day at
which samples were collected was variable, and there were no dietary or
pharmacologic restrictions because it was presumed that metabolites would be
sufficiently altered between analysis and that the stable state would serve as a
control reference for exacerbations. Actually, these conditions are more
representative of a real-life situation because exacerbations can take place at
any time of the day.
Urine analysis using SPME/GC 3 GC-ToFMS
Urine samples were analyzed by means of SPME, followed by compre-
hensive GC 3 GC-ToFMS. The SPME experimental parameters used to
extract urine metabolites and the GC 3 GC-ToFMS conditions have been
previously reported by Rocha et al.E2 Each sample was analyzed in triplicate.
(GC3GC-ToFMS is a highly reproducible techniquewith a limit of detection
at the picogram per liter level using standards. Spiking experiments have not
been performed for quantification purposes.) The deconvoluted total ion cur-
rent GC3GC area data were used as an approach to estimate the relative con-
tent of each metabolite in the urine samples. Each total ion chromatogramwas
processed by using the automated data processing software ChromaTOF
(LECO), which allows an area for each analyte to be obtained. No automatic
alignment of the chromatograms was performed.
Urine analysis using 1H-NMR
The 1H-NMRmethodology was applied to 5 of 10 subjects for which sam-
ples were available. For the NMR analysis, each thawed sample was buffered
to pH 7.0, according to Carrola et al.E3 Each sample was analyzed once
because NMR is a highly reproducible technique. (The limit of detection
with a standard [noncryogenic] probe is in the low micromolar range. Spiking
experiments have not been performed for quantification purposes.)
Statistical analysis
PCA is a nonsupervised method aimed at exploring data variability and
detecting intrinsic clustering and outliers. The distribution of samples in the
score maps allows one to infer on the similarity between the samples’
composition. Both intraindividual and interindividual variability can be
assessed when including replicate samples from different subjects. Score
scatter plots were used to visualize and explore the relationships among
samples, whereas loadings profile plots were used to inspect the variables
(metabolites) that contributed the most in the observed group distribution.
GC 3 GC-ToFMS data. The GC3 GC peak areas data set consisted of
60 observations (3 replicate analyses from 20 urine samples, 2 from each of 10
subjects, at 2 clinical states [stable and exacerbation]) and 32 variables (peak
areas of aliphatic aldehydes and alkanes). A list of the specific compounds
included is provided in Table E2.
1H-NMR data. Variably sized bucketing was performed in the 10.00- to
0.40-ppm region of the standard 1D spectra (excluding the subregion d 4.55-
6.05, corresponding towater and urea signals). Each spectrumwas normalized
to total area, and the data were scaled to unit variance (to give all variables the
same weight).
Given the small sample numbers, we have applied PCA to only the data, a
method inwhich classmembership is not included in themodeling process, and
we have purposely avoided supervised methods, such as partial least squares-
discriminant analysis, whichwould carry a high risk of overfitting. Futurework
comprising a larger sample set will address the predictive ability and
classification rate of the multivariate models.
Results and discussion
Limitations and strengths. As suggested by Reisdorph and Wech-
sler,E4 studies targeting single molecules do not capture the network of asthma
processes. One of the novel and key points of this study is the complementary
use of these 2 high-throughput techniques because they provide information
on different windows of the urinary metabolome.
Data interpretation. Alkanes and aldehydes, in the sequence of
oxidation reactions, are end products that have been associated with oxidative
stress and inflammatory processes. The obtained results suggest that the
oxidative state is at a higher extent in exacerbation when comparedwith that in
the stable condition.
The results of patient 9 might be explained by his clinical profile, which has
led to a high and constant burden of oxidative stress. His related exacerbation
was driven by persistent noncontrolled rhinitis and nasal polyposis, with no
related allergen exposure or known viral infection.
A plausible confounding factor for molecular mechanisms is his hyper-
sensitivity to aspirin. Increased urinary eicosanoids, a group of molecules
produced by oxidative processes from arachidonic acid, have already been
implicated in asthma exacerbation, and the arachidonic acid cycle is related to
the tricarboxylic acid cycle (alkanes can arise as products of lipid peroxidation
of unsaturated fats, as already stated). Furthermore, isoprostanes are bioactive
prostaglandin F2–like compounds, produced independently of the COX en-
zymes through the peroxidation of arachidonic acid, which has been already
implicated in asthma exacerbation,E5 and are potent constrictors of smooth
muscle, which can explain the patient’s persistent airflow obstruction.
A recent study by Paredi et alE6 demonstrated that concentrations of exhaled
ethane (a lipid peroxidation marker) were increased in patients with more
severe bronchoconstriction (FEV1 < 60%) compared with less constricted
patients (FEV1 >_ 60%).
Clinical importance of the study. Despite the small sample of the
study, the authors, based on these preliminary findings, are convinced that this
approach can be successfully applied to a broader investigation of asthmatic
patients with different phenotypes and disease presentation.
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FIG E1. Each line corresponds to 1 metabolite (organized by aldehydes and alkanes chemical families), and
each column corresponds to each subject (organized by stable state and exacerbation conditions).
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FIG E2. 1H-NMR spectra (500 MHz) of urine from patient 10 in the stable state (A) and in exacerbation con-
ditions (B; each spectrum is normalized to total area). Vertical expansions (63) of aliphatic and aromatic
subregions are shown. Signal assignment: 1, 3-hydroxy-isovalerate; 2, threonine and lactate; 3,
2-hydroxyisobutyrate; 4, alanine; 5, lysine; 6, acetate; 7, N-acetylated amino acids; 8, acetylcarnitine; 9,
p-cresol sulphate; 10, citrate; 11, dimethylamine (DMA); 12, dimethylglycine (DMG); 13, creatine; 14, creat-
inine; 15, malonate; 16, carnitine; 17, trimethylamine-N-oxide (TMAO); 18, glycine; 19, hippurate; 20,
glucose; 21, urea; 22, histidine; 23, 3-methylhistidine; 24, phenylacetylglutamine (PAG); 25, indoxylsulfate;
26, hypoxanthine; 27, formate.
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TABLE E1. Individual patients’ characteristics
Patient
no. Age (y) Sex
FEV1
(% predicted),*
before BD ACT Atopy
NMR
analysis
1 57 M 35 24 Pollens No
2 64 F 148 20 Mites Yes
3 39 F 65 22 Mites, pollens Yes
4 71 M 83 24 No Yes
5 23 F 102 25 Mites, pollens Yes
6 69 F 37 20 No No
7 22 M 103 25 Mites No
8 40 M 92 23 Mites No
9 59 M 78 20 No Yes
10 58 F 132 20 Mites No
ACT, Asthma Control Test; BD, bronchodilator; F, female; M, male.
*Percent predicted FEV1/forced vital capacity after bronchodilation.
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TABLE E2. Urinary aliphatic alkanes and aldehydes identified by using HS-SPME/GC3 GC-ToFMS and selected for multivariate analysis
1tR* (s)
2tR* (s) Compounds CAS no. RIcalcy RIlitz
Alkanes
90 0.34 2-Methylpentane 107-83-5 587 558
102 0.34 Hexane§ 110-54-3 600 600
222 0.43 4-Methylheptane 589-53-7 738 765
276 0.41 Octane§ 111-65-9 800 800
324 0.45 2,4-Dimethylheptane 2213-23-2 819 822
498 0.43 Nonane§ 111-84-2 900 900
666 0.41 2,2,4,6,6-Pentamethylheptane 13475-82-6 991 997
684 0.42 Decane§ 124-18-5 1000 1000
840 0.46 Undecane§ 1120-21-4 1105 1100
972 0.43 Dodecane§ 112-40-3 1200 1200
1098 0.47 Tridecane§ 629-50-5 1300 1300
1212 0.48 Tetradecane§ 629-59-4 1401 1400
1314 0.45 Pentadecane§ 629-62-9 1500 1500
1416 0.46 Hexadecane§ 544-76-3 1601 1600
1464 0.48 2,6,10-Trimethylpentadecane 3892-00-0 1651 1649
1512 0.51 Heptadecane§ 629-78-7 1701 1700
1602 0.46 Octadecane§ 593-45-3 1808 1800
1686 0.50 Nonadecane§ 629-92-5 1901 1900
1770 0.49 Eicosane§ 112-95-8 2001 2000
Aldehydes
126 0.55 3-Methylbutanal 590-86-3 628 646
132 0.53 2-Methylbutanal 96-17-3 635 646
150 0.62 Pentanal§ 110-62-3 656 697
276 0.97 Hexanal§ 66-25-1 800 800
504 0.98 Heptanal§ 111-71-7 904 899
606 0.76 2-Ethylhexanal 123-05-7 958 955
690 0.81 Octanal§ 124-13-0 1004 1001
846 0.82 Nonanal§ 124-19-6 1105 1098
978 0.80 Decanal§ 112-31-2 1205 1204
1104 0.73 Undecanal§ 112-44-7 1306 1291
1218 0.73 Dodecanal§ 112-54-9 1407 1407
1428 0.72 Tetradecanal 124-25-4 1613 1611
1614 0.76 Hexadecanal 629-80-1 1815 1819
CAS, Chemical Abstracts Service.
*Retention times in seconds for first (1tR) and second (
2tR) dimensions.
Retention index obtained through the modulated chromatogram.
Retention index reported in the literature for 1-dimensional GC with a 5%-phenyl-methylpolysiloxane GC column or equivalent and for a comprehensive GC 3 GC system with
HP-5 for the first dimension.
§Compound confirmed by means of coinjection of chemical standards.
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